ABSTRACT

Introduction: Cardiometabolic diseases are a global public health problem, with significant increases in their prevalence. Different epigenetic factors involved in the progression of metabolic alterations have been described, such as long non-coding RNAs (lncRNAs). H19 is a multifunctional lncRNA expressed from the maternal allele, with low expression after birth, except in the skeletal muscle and heart. Recent studies have linked its dysregulation to alterations in cell metabolism.

Areas covered: H19 plays a role in the pathogenesis of coronary artery disease, nonalcoholic fatty liver disease, hepatic and renal fibrosis, insulin resistance, type 2 diabetes, and inflammation. H19 acts mainly as a competitive endogenous RNA of molecules involved in pathways that regulate cell metabolism. In this review, we analyzed the dysregulation of H19 in cardiometabolic diseases and its relationship with molecular alterations in different signaling pathways.

Expert opinion: The association of H19 with the development of cardiometabolic diseases, indicates that H19 could be a therapeutic target and prognostic biomarker for these diseases. Controversies have been reported regarding the expression of H19 in some metabolic diseases, therefore, it is necessary to continue research to clarify its pathogenic effect in different organs.

摘要

简介：心脏代谢疾病是一个全球性的公共卫生问题，其患病率显着增加。已经描述了参与代谢改变进展的不同表观遗传因素，例如长链非编码 RNA (lncRNA)。H19是由母体等位基因表达的多功能lncRNA，出生后表达量较低，骨骼肌和心脏除外。最近的研究已将其失调与细胞代谢的改变联系起来。

涵盖的领域：H19 在冠状动脉疾病、非酒精性脂肪性肝病、肝肾纤维化、胰岛素抵抗、2 型糖尿病和炎症的发病机制中发挥作用。H19 主要作为参与调节细胞代谢途径的分子的竞争性内源性 RNA。在这篇综述中，我们分析了心脏代谢疾病中 H19 的失调及其与不同信号通路分子改变的关系。

专家意见：H19 与心脏代谢疾病发展的关联表明 H19 可能是这些疾病的治疗靶点和预后生物标志物。H19在某些代谢性疾病中的表达存在争议，因此，有必要继续研究以阐明其在不同器官中的致病作用。